BACKGROUND: In studies from high-income countries, human immunodeficiency virus type 1 (HIV-1)-infected persons have diminished responses to hepatitis B virus (HBV) vaccination, compared with HIV-1-uninfected persons, but data from other settings are limited. METHODS: We compared the immune response to HBV vaccination among HIV-1-infected and HIV-1-uninfected Kenyan adults and assessed the response of HIV-1-infected initial nonresponders to revaccination with a standard HBV vaccine series. RESULTS: Of 603 participants, 310 (51.4%) were HIV-1-infected, for whom the median CD4(+) T-cell count was 557 cells/μL (interquartile range, 428-725 cells/μL); none were receiving antiretroviral therapy. Nonresponse to HBV vaccine was higher among HIV-1-infected participants, compared with HIV-1-uninfected participants (35.8% vs 14.3%; odds ratio, 3.33; P < .001). Of 102 HIV-1-infected initial nonresponders, 88 (86.3%) responded to revaccination, for an overall response, including to revaccination, of 94.9%. Among HIV-1-infected individuals, lower CD4(+) T-cell counts and male sex were independent predictors of nonresponse to initial vaccination, and lower body mass index, higher plasma HIV-1 RNA levels, and longer time to revaccination predicted nonresponse to revaccination. CONCLUSIONS: Kenyan adults had similar HBV vaccination responses as persons from high-income countries. Timely revaccination of HIV-1-infected nonresponders increased response to the vaccine to 95%.
BACKGROUND: In studies from high-income countries, human immunodeficiency virus type 1 (HIV-1)-infectedpersons have diminished responses to hepatitis B virus (HBV) vaccination, compared with HIV-1-uninfectedpersons, but data from other settings are limited. METHODS: We compared the immune response to HBV vaccination among HIV-1-infected and HIV-1-uninfected Kenyan adults and assessed the response of HIV-1-infected initial nonresponders to revaccination with a standard HBV vaccine series. RESULTS: Of 603 participants, 310 (51.4%) were HIV-1-infected, for whom the median CD4(+) T-cell count was 557 cells/μL (interquartile range, 428-725 cells/μL); none were receiving antiretroviral therapy. Nonresponse to HBV vaccine was higher among HIV-1-infectedparticipants, compared with HIV-1-uninfectedparticipants (35.8% vs 14.3%; odds ratio, 3.33; P < .001). Of 102 HIV-1-infected initial nonresponders, 88 (86.3%) responded to revaccination, for an overall response, including to revaccination, of 94.9%. Among HIV-1-infected individuals, lower CD4(+) T-cell counts and male sex were independent predictors of nonresponse to initial vaccination, and lower body mass index, higher plasma HIV-1 RNA levels, and longer time to revaccination predicted nonresponse to revaccination. CONCLUSIONS: Kenyan adults had similar HBV vaccination responses as persons from high-income countries. Timely revaccination of HIV-1-infected nonresponders increased response to the vaccine to 95%.
Authors: D Rey; V Krantz; M Partisani; M P Schmitt; P Meyer; E Libbrecht; M J Wendling; D Vetter; M Nicolle; G Kempf-Durepaire; J M Lang Journal: Vaccine Date: 2000-01-18 Impact factor: 3.641
Authors: Edgar Turner Overton; Somnuek Sungkanuparph; William G Powderly; Warren Seyfried; Richard K Groger; Judith A Aberg Journal: Clin Infect Dis Date: 2005-08-22 Impact factor: 9.079
Authors: Robert C Bollinger; Chloe L Thio; Mark S Sulkowski; Jane McKenzie-White; David L Thomas; Charles Flexner Journal: Lancet HIV Date: 2019-12-20 Impact factor: 12.767
Authors: Michael Osthoff; Elizabeth Irungu; Kenneth Ngure; Nelly Mugo; Katherine K Thomas; Jared M Baeten; Damon P Eisen Journal: Vaccine Date: 2014-07-10 Impact factor: 3.641
Authors: E Seremba; P Ocama; R Ssekitoleko; H Mayanja-Kizza; S V Adams; J Orem; E Katabira; S J Reynolds; R Nabatanzi; C Casper; W Phipps Journal: Vaccine Date: 2021-01-28 Impact factor: 3.641
Authors: Kahtonna Allen; Octavio Mesner; Anuradha Ganesan; Thomas A O'Bryan; Robert G Deiss; Brian K Agan; Jason F Okulicz Journal: BMC Infect Dis Date: 2015-05-01 Impact factor: 3.090
Authors: Mark K Webale; Mark W Kilongosi; Valentine Budambula; Raphael Lihana; Francis O Musumba; Anthony K Nyamache; Nancy L M Budambula; Aabid A Ahmed; Collins Ouma; Tom Were Journal: BMC Infect Dis Date: 2015-07-30 Impact factor: 3.090